Novavax reports efficacy of 96.4% on original virus

Novavax: US-Based Bio-technology Company

Current project: Development of a recombinant vaccine for COVID-19

Latest Announcement:

A final efficacy of 96.4% against mild, moderate and severe disease caused by the original SARSCoV­2 strain in a pivotal Phase­3 trial in the U.K.

Previous Announcements:

In January, the company reported that its vaccine had proved to have 89% effi­cacy in preventing infection in some trial volunteers in the U.K.

Indian Relations:

The Serum Institute of India has an agreement with Novavax to manufacture a substantial volume of the vaccine.

Author: UINDO

Leave a Reply

Your email address will not be published. Required fields are marked *